MSLN and breast cancer: Among these strategies, the feasibility of combinatorial antigen recognition approach has been confirmed in the different solid tumors, including HER2+MUC1+ breast cancer [12], PSCA+PSMA+ prostate cancer [8], GPC3+ASGR1+ hepatocellular carcinoma [13] and CEA+MSLN+ pancreatic cancer [14].